ÂÜÀòÂÒÂ×

David Lloyd is currently the VP Metabolic Disease at insitro, utilizing advanced machine-learning in clinical and cellular datasets to uncover new insights into metabolic diseases and develop prediction models for therapeutic candidates. Prior to this role, David held positions at Carmot Therapeutics, Inc., and Amgen, where David led various drug discovery and preclinical programs related to diabetes, obesity, and dyslipidemia. With a background in genetics and a Ph.D. from the University of Leicester, David has also contributed to the field through postdoctoral work at GNF.